![]() ![]() Premier Forms Pitocin Supply Partnership With Endo InternationalĮndo International plc Launches First Generic Version of Noxafil® (posaconazole) InjectionĮndo International plc Announces Approval of XCOPRI (Cenobam Tablets) in CanadaĮndo International plc Announces First Patient Enrolled in Registry of Dupuytren's ContractureĮndo International plc Launches Dexlansoprazole Capsules, Generic Version of DexilantĮndo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Second Motion for Exclusivity Period Extension Approved For Endo International plcīankrupt Endo says US government objections imperil $600 million in opioid settlements Tranche Update on Endo International plc (OTCPK:ENDP.Q)'s Equity Buyback Plan announced on April 30, 2015.Įndo International plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023Įarnings Flash (ENDP) ENDO INTERNATIONAL Posts Q2 Revenue $547MĮarnings Flash (ENDP) ENDO INTERNATIONAL Reports Q2 EPS $0.98 Rite Aid joins companies going bankrupt amid opioid litigation Third Motion for Exclusivity Period Extension Approved For Endo International plcĮndo International plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023Įndo International plc Revises Earnings Guidance for the Year 2023Įarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q3 EPS $0.56Įarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q3 Revenue $451.7M Diluted loss per share was USD 11.42 compared to USD 0.22 a year ago. Basic loss per share was USD 11.42 compared to USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 11.35 compared to USD 0.05 a year ago. Basic loss per share from continuing operations was USD 11.35 compared to USD 0.05 a year ago. Net loss was USD 2,679.57 million compared to USD 51.18 million a year ago. Diluted loss per share was USD 3.07 compared to USD 0.33 a year ago.įor the nine months, sales was USD 1,763.06 million compared to USD 2,203.78 million a year ago. Basic loss per share was USD 3.07 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 3.05 compared to USD 0.21 a year ago. Basic loss per share from continuing operations was USD 3.05 compared to USD 0.21 a year ago. Net loss was USD 722.17 million compared to USD 77.21 million a year ago. For the third quarter, the company reported sales was USD 541.69 million compared to USD 772.03 million a year ago. ![]() The data presented on this page does not represent the view of Endo Pharmaceuticals Inc and its employees or that of Zippia.Įndo Pharmaceuticals Inc may also be known as or be related to ENDO HEALTH SOLUTIONS INC., Endo Health Solutions Inc, Endo Health Solutions Inc., Endo International plc, Endo Pharmaceuticals and Endo Pharmaceuticals Inc.Endo International plc reported earnings results for the third quarter and nine months ended September 30, 2022. None of the information on this page has been provided or approved by Endo Pharmaceuticals Inc. ![]() While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. The employee data is based on information from people who have self-reported their past or current employments at Endo Pharmaceuticals Inc. Zippia gives an in-depth look into the details of Endo Pharmaceuticals Inc, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Endo Pharmaceuticals Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |